Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
The oncologist（2023）
摘要
Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.
更多查看译文
关键词
axitinib,metastatic renal cell carcinoma,sorafenib,tivozanib,vascular endothelial growth factor inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要